How to Read 13F Filings: A Biotech Investor's Complete Guide

SEC Form 13F is a quarterly disclosure required of institutional investment managers who exercise investment discretion over $100 million or more in qualifying assets. The filing shows every long equity position the fund holds as of the last day of the calendar quarter. The filing schedule follows a predictable cadence: Q4 filings are due by February 14, Q1 by May 15, Q2 by August 14, and Q3 by November 14 — always 45 days after the quarter ends. Each filing lists the security name, CUSIP number, number of shares held, and market value as of quarter end. For biotech investors, 13F filings are the primary window into what specialist hedge funds are doing with their capital. Funds like Baker Brothers, Perceptive Advisors, OrbiMed, and RA Capital manage billions of dollars with dedicated biotech research teams — their portfolio decisions reflect months of clinical analysis, regulatory assessment, and management due diligence.

The SEC's EDGAR system (efts.sec.gov) is the authoritative source. You can search by fund name or CIK number to find any manager's filing history. There are three form types to know: 13F-HR is the standard holdings report — this is the one you want. 13F-HR/A is an amendment, filed when a fund corrects errors in a prior filing. 13F-NT is a notice of late filing, which means the fund is requesting extra time (often a sign of portfolio restructuring or operational issues). Raw EDGAR filings are delivered in XML format and are difficult to parse manually. This is one reason tools like BiotechEdge exist — we ingest every 13F filing from tracked specialist funds, parse the XML into structured data, and calculate quarter-over-quarter position changes automatically.

Each line in the 13F information table contains: CUSIP — the unique 9-character identifier for each security. This is how the SEC tracks positions across filings. Issuer name and class — the company name and share class (common stock, preferred, ADR). Some biotech companies have multiple classes of stock, which can create confusion if you're not careful. Shares or principal amount — the number of shares held as of quarter end. This is the most actionable field for tracking position changes over time. Value (in thousands) — the market value of the position on the last trading day of the quarter. This is not cost basis. A fund reporting $50M in value for a position could be sitting on a 200% gain or a 50% loss — you cannot tell from the 13F alone. Investment discretion — whether the fund has sole, shared, or defined discretion over the position. Sole discretion means the fund's portfolio manager made the decision independently. Voting authority — how many shares the fund can vote. This matters for proxy contests and activist situations.

The most common objection to using 13F data is the filing delay. By the time you see a fund's Q1 positions, it's mid-May — the fund could have already changed its mind. In most sectors, this is a valid concern. But in biotech, the delay matters less for two reasons: Specialist biotech funds hold positions for extended periods. Verdad Capital's 2026 white paper found that top-quintile specialist fund holdings had average holding periods measured in years, not months. A new position in Q1 is very likely still held in Q2. Biotech catalysts operate on long timelines. A fund that builds a position ahead of a Phase 3 readout expected in Q4 is not going to exit in Q2. The clinical development cycle means the thesis takes quarters to play out — the 45-day delay is a small fraction of the investment horizon. Cohen, Malloy & Pomorski (2012) confirmed this more broadly: the most informative institutional trades are those that persist across multiple quarters, precisely because they reflect deep conviction rather than tactical trading.

The real value of 13F data comes from comparing consecutive filings. There are four types of changes to track: New positions — the stock appears in the current filing but not the prior quarter. This is the strongest signal: it represents a fresh conviction decision. The fund's research team analyzed the company and decided to deploy capital. Increased positions — share count is up 10% or more from the prior quarter. This signals growing conviction. In biotech, increases often correspond to building a position ahead of a known catalyst. Decreased positions — share count is down 10% or more. This can reflect profit-taking, risk management, or fading conviction. Decreases are informative but noisier than new positions — a fund might trim for portfolio construction reasons unrelated to the specific stock. Exits — the stock was in the prior quarter filing but is completely absent now. An exit is a definitive statement that the fund no longer wants exposure. In biotech, exits around clinical catalysts are especially meaningful. When multiple specialist funds independently make the same move in the same quarter — three funds all initiate new positions in the same company — the signal is particularly strong. This is what BiotechEdge calls fund convergence.

13F data has important blind spots: No short positions. The 13F only reports long holdings. You cannot see which stocks a fund is betting against. Short interest data from FINRA provides a partial view, but not attributed to specific funds. Limited options detail. Funds report put and call positions, but not strike prices, expirations, or whether they're hedging or speculating. A large put position could be a bearish bet or downside protection on a long position. No intra-quarter activity. A fund could have bought 1 million shares, sold them all, and repurchased — the 13F only shows the end-of-quarter snapshot. Confidential treatment requests. Funds can petition the SEC to delay disclosure of specific positions for up to a year. This is rare but tends to happen with the most interesting positions — exactly the ones you'd want to see. US-listed equities only. 13F covers US exchange-listed stocks. Foreign holdings, private placements, bonds, and warrants are not reported. Some biotech funds hold significant positions in foreign-listed companies that never appear in 13F data. 13D/13G for large positions. When a fund crosses 5% ownership, they must file a Schedule 13D or 13G within 10 days — much faster than the quarterly 13F. These filings provide more timely data for significant positions.

The academic and industry evidence points to a clear framework: track what specialist biotech funds are doing, focus on new and increasing positions, and pay attention when multiple funds converge on the same company. The highest-value use of 13F data in biotech is fund convergence — when 3 or more dedicated biotech funds independently build positions in the same stock. See our convergence page for live data and our analysis of why specialist fund holdings predict returns. Each fund has its own research team, its own clinical analysis, and its own risk framework. When they arrive at the same conclusion independently, the signal compounds. BiotechEdge tracks 20 specialist biotech hedge funds, parses every quarterly filing within hours of publication on EDGAR, and surfaces new positions, exits, convergence signals, and AI-generated context automatically. Combined with insider trading data (Form 4), catalyst calendars (ClinicalTrials.gov), and short interest (FINRA), the 13F becomes one dimension of a multi-signal framework — not a standalone indicator, but the foundation of a complete picture.